Uncategorized

Coalition to Cure Calpain 3 and Muscular Dystrophy Association partner to fund gene therapy grant

Muscular Dystrophy Association (MDA) and Coalition to Cure Calpain 3 (C3) partner to fund $300,000 research grant for gene therapy development in limb-girdle muscular dystrophy. This grant supports the work of Melissa Spencer, PhD, Director of the Neuromuscular Division in

Upcoming webinar: The Power of Data Sharing and Collaboration Across LGMDs in a Pre-Competitive, Neutral Environment

Thursday, December 12 at 11 AM EST This event will feature Dr. Volker Straub, a renowned neuromuscular genetics expert, Director of the John Walton Muscular Dystrophy Research Centre at Newcastle University, and member of C3’s Scientific Advisory Board. Dr. Straub will

C3 Scientific Meeting Recap

Coalition to Cure Calpain 3 (C3) recognizes that collaboration and data sharing are integral to drug discovery and therapy development. To foster these interactions, we hosted an in-person meeting focused on advances in clinical trial readiness and treatment development for

Vita Therapeutics letter to the LGMD2A/R1 community

Today, Vita Therapeutics published an open letter to the LGMD2A/R1 community announcing some important changes to their development plans.

Trial readiness study for individuals with LGMD2A/R1

Please contact either Ruby Langeslay or Jennifer Raymond at Virginia Commonwealth University for more information

Countdown to the New Year – 2023 Edition

This year, C3 collaborated with 5 other LGMD organizations to publish the Voice of the Patient Report, summarizing the 2022 Externally-Led Patient Focused Drug Development Meeting and highlighting the unmet medical needs of the LGMD community. READ MORE Connected with

Coalition to Cure Calpain 3 in partnership with the National Organization for
Rare Disorders (NORD®) launches LGMD2A/Calpainopathy Registry

Today, Coalition to Cure Calpain 3 (C3) in partnership with the National Organization for Rare Disorders (NORD®) launched a study with global reach to research Calpainopathy (including limb-girdle muscular dystrophy type 2A/LGMDR1 and limb-girdle muscular dystrophy type 1I/LGMDD4), a rare

Vita Therapeutics enters licensing agreement with MilliporeSigma

Today, Vita Therapeutics announced they entered a licensing agreement with MilliporeSigma to advance their cell therapy program to treat LGMD2A/R1. This agreement allows Vita to utilize MilliporeSigma’s CRISPR gene editing patents to insert a functional copy of the CAPN3 gene

Publication shares development of new animal model of LGMD2A/R1

A paper published by Jason Berman, Children’s Hospital of Eastern Ontario Research Institute and University of Ottawa, along with colleagues from Dalhousie University, AGADA Biosciences, and Binghamton University – State University of New York, shares the development of a zebrafish

Travel Grant Program for Early Career Investigators

Coalition to Cure Calpain 3 will award Travel Grants to foster early career investigators who are currently conducting research in the areas of limb-girdle muscular dystrophy type 2A (LGMD2A/R1) or Calpain 3. The grants support travel expenses to attend relevant

« Previous